Sensible Bio raises $47 million Series A to build mRNA therapy manufacturing platform
read at Endpoints ↗DealPositive
Sensible Biotechnologies announced it has closed a $47 million Series A financing round. The capital will be used to develop its proprietary manufacturing platform for mRNA based therapies.
The funding comes as the market for mRNA therapeutics continues to expand, and the company aims to improve efficiency and scalability of drug production.
Chief scientific officer Marian Kupculak and CEO Miroslav Gasparek said the new platform will help the firm mark its territory in the hot mRNA space.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform”
read at Endpoints ↗92 words · retrieved 57m ago
comments(0)
5-min edit window · permanent after that